Spectrum and Immunophenotypic Profile of Acute Leukemia: A Tertiary Center Flow Cytometry Experience.
AML
AUL
B-ALL
FLT3/NPM1c
MPAL
T-ALL
Journal
Mediterranean journal of hematology and infectious diseases
ISSN: 2035-3006
Titre abrégé: Mediterr J Hematol Infect Dis
Pays: Italy
ID NLM: 101530512
Informations de publication
Date de publication:
2019
2019
Historique:
received:
17
09
2018
accepted:
19
01
2019
entrez:
13
3
2019
pubmed:
13
3
2019
medline:
13
3
2019
Statut:
epublish
Résumé
For diagnosis, sub-categorization and follow up of Acute Leukemia (AL), phenotypic analysis using flow cytometry is mandatory. We retrospectively analyzed immunophenotypic data along with cytogenetics/molecular genetics data (wherever available) from 631 consecutive cases of AL diagnosed at our flow cytometry laboratory from January 2014 to August 2017. Of the total 631 cases, 52.9% (n=334) were acute lymphoblastic leukemia (ALL), 43.9% (n=277) acute myeloid leukemia (AML), 2.2% (n=14) mixed phenotypic acute leukemia (MPAL), 0.5% (n=3) acute undifferentiated leukemia (AUL) and 0.5% (n=3) chronic myeloid leukemia in blast crisis (CML-BC). ALL cases comprised of 81.7% (n=273/334) B-cell ALLs (95.2%, n=260/273 common B-ALLs and 4.8%, n=13/273 Pro B-ALLs). CD13 was the commonest cross lineage antigen, expressed in B-ALL (25.6%, n=70/273), followed by CD33 (17.9%, n=49) and combined CD13/CD33 (11.3%, n=31/273) expression. T-ALLs constituted 18.3% (n=61/334) of total ALLs and included 27.9% (n=17/61) cortical T- ALLs. CD13 was commonest (32.7%, n=20/61) aberrantly expressed antigen in T-ALLs, followed by CD117 (19.1%, n=9/47). AML cases included 32.1% (n=89/277) AML with recurrent genetic abnormalities, 9.0% (n=25/277) with FLT3/NPM1c mutation and 58.9% (n=163/277) AML NOS including 14.7% (n=24/163) AML M4/M5, 1.8% (n=3/163) AML M6 and 3.7% (n=6/163) AML M7. In AMLs, CD19 aberrancy was the most common (20.2%, n=56/277) followed by CD56 (15.8%, n=42/265). In this study, we document the spectrum, correlate the immunophenotype with genetic data of all leukemias, especially concerning T-ALL where the data from India is scarce.
Sections du résumé
BACKGROUND
BACKGROUND
For diagnosis, sub-categorization and follow up of Acute Leukemia (AL), phenotypic analysis using flow cytometry is mandatory.
MATERIAL AND METHODS
METHODS
We retrospectively analyzed immunophenotypic data along with cytogenetics/molecular genetics data (wherever available) from 631 consecutive cases of AL diagnosed at our flow cytometry laboratory from January 2014 to August 2017.
RESULTS
RESULTS
Of the total 631 cases, 52.9% (n=334) were acute lymphoblastic leukemia (ALL), 43.9% (n=277) acute myeloid leukemia (AML), 2.2% (n=14) mixed phenotypic acute leukemia (MPAL), 0.5% (n=3) acute undifferentiated leukemia (AUL) and 0.5% (n=3) chronic myeloid leukemia in blast crisis (CML-BC). ALL cases comprised of 81.7% (n=273/334) B-cell ALLs (95.2%, n=260/273 common B-ALLs and 4.8%, n=13/273 Pro B-ALLs). CD13 was the commonest cross lineage antigen, expressed in B-ALL (25.6%, n=70/273), followed by CD33 (17.9%, n=49) and combined CD13/CD33 (11.3%, n=31/273) expression. T-ALLs constituted 18.3% (n=61/334) of total ALLs and included 27.9% (n=17/61) cortical T- ALLs. CD13 was commonest (32.7%, n=20/61) aberrantly expressed antigen in T-ALLs, followed by CD117 (19.1%, n=9/47). AML cases included 32.1% (n=89/277) AML with recurrent genetic abnormalities, 9.0% (n=25/277) with FLT3/NPM1c mutation and 58.9% (n=163/277) AML NOS including 14.7% (n=24/163) AML M4/M5, 1.8% (n=3/163) AML M6 and 3.7% (n=6/163) AML M7. In AMLs, CD19 aberrancy was the most common (20.2%, n=56/277) followed by CD56 (15.8%, n=42/265).
CONCLUSIONS
CONCLUSIONS
In this study, we document the spectrum, correlate the immunophenotype with genetic data of all leukemias, especially concerning T-ALL where the data from India is scarce.
Identifiants
pubmed: 30858955
doi: 10.4084/MJHID.2019.017
pii: mjhid-11-1-e2019017
pmc: PMC6402547
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e2019017Déclaration de conflit d'intérêts
Competing interests: The authors have declared that no competing interests exist.
Références
Ann Oncol. 1999 Feb;10(2):167-76
pubmed: 10093685
Leukemia. 2000 Jan;14(1):163-8
pubmed: 10637492
Blood. 2000 Aug 1;96(3):870-7
pubmed: 10910899
Blood. 2000 Aug 15;96(4):1287-96
pubmed: 10942370
Leukemia. 2001 Mar;15(3):406-14
pubmed: 11237064
J Biol Regul Homeost Agents. 2001 Jan-Mar;15(1):68-78
pubmed: 11388747
Leuk Res. 2004 Jan;28(1):43-8
pubmed: 14630079
Indian J Cancer. 2003 Apr-Jun;40(2):71-6
pubmed: 14716122
Zhonghua Er Ke Za Zhi. 2003 May;41(5):334-7
pubmed: 14751050
Ai Zheng. 2005 Jun;24(6):667-71
pubmed: 15946475
Haematologica. 2007 Mar;92(3):342-8
pubmed: 17339183
Int J Clin Exp Pathol. 2008 Jan 01;1(2):124-33
pubmed: 18784805
Cytometry B Clin Cytom. 2009 May;76(3):199-205
pubmed: 18803279
Pediatr Hematol Oncol. 2009 Jun;26(4):216-31
pubmed: 19437324
Clin Exp Med. 2010 Mar;10(1):33-40
pubmed: 19779962
Blood. 2009 Dec 10;114(25):5136-45
pubmed: 19828704
Am J Clin Pathol. 2009 Dec;132(6):940-9
pubmed: 19926587
Int J Pediatr. 2009;2009:674801
pubmed: 20041009
Am J Clin Pathol. 2011 Jan;135(1):76-84
pubmed: 21173127
Blood. 2011 Mar 17;117(11):3163-71
pubmed: 21228332
Haematologica. 2012 Nov;97(11):1708-12
pubmed: 22581002
J Oncol. 2012;2012:135186
pubmed: 23227046
Indian J Hematol Blood Transfus. 2012 Jun;28(2):89-96
pubmed: 23730015
Indian J Hematol Blood Transfus. 2014 Mar;30(1):16-8
pubmed: 24554814
Exp Hematol Oncol. 2014 Jun 13;3:16
pubmed: 24949228
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Jun;22(3):634-9
pubmed: 24989267
Mediterr J Hematol Infect Dis. 2014 Nov 01;6(1):e2014073
pubmed: 25408859
Blood. 2016 Apr 14;127(15):1863-9
pubmed: 26747249
Exp Hematol. 2016 Aug;44(8):740-4
pubmed: 27208809
Turk J Haematol. 2006 Sep 5;23(3):151-7
pubmed: 27265483
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Indian J Pathol Microbiol. 2017 Jan-Mar;60(1):43-49
pubmed: 28195090
Cytometry B Clin Cytom. 2018 May;94(3):468-476
pubmed: 29220871
Blood. 1997 Jul 15;90(2):571-7
pubmed: 9226156
Am J Clin Pathol. 1998 Feb;109(2):211-20
pubmed: 9583894